Webcast Replay Is Available: Elan Reports Third Quarter 2011 Financial Results

• Webcast

Alzheimer’s Disease

• ELND005, Phase II Studies. More.  

Crohn’s Disease

• TYSABRI INFORM Study. More.

BioNeurology
products and pipeline.
View.

01/26/2012: ASCEND Study to Evaluate the Effectiveness of TYSABRI® (natalizumab) as a Treatment for Secondary-Progress... More.

01/25/2012: Elan Announces Webcast of Fourth Quarter and Full-Year 2011 Financial Results More.

01/20/2012: FDA Updates TYSABRI® (natalizumab) Label to Include Anti-JC Virus Antibody Status as a PML Risk Factor More.